@article{97a4ae83c838415daa720e611e34287c,
title = "MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage",
abstract = "MR1-restricted T cells (MR1Ts) are a T cell subset that recognize and mediate host defense to a broad array of microbial pathogens, including respiratory pathogens (e.g., Mycobacterium tuberculosis, Streptococcus pyogenes, and Francisella tularensis) and enteric pathogens (e.g., Escherichia coli and Salmonella species). Mucosal-associated invariant T (MAIT) cells, a subset of MR1Ts, were historically defined by the use of a semi-invariant T cell receptor (TCR) and recognition of small molecules derived from the riboflavin biosynthesis pathway presented on MR1. We used mass spectrometry to identify the repertoire of ligands presented by MR1 from the microbes E. coli and Mycobacterium smegmatis. We found that the MR1 ligandome is unexpectedly broad, revealing functionally distinct ligands derived from E. coli and M. smegmatis. The identification, synthesis, and functional analysis of mycobacterial ligands reveal that MR1T ligands can be distinguished by MR1Ts with diverse TCR usage. These data demonstrate that MR1 can serve as an immune sensor of the microbial ligandome.",
author = "Harriff, {Melanie J.} and Curtis McMurtrey and Froyd, {Cara A.} and Haihong Jin and Meghan Cansler and Megan Null and Aneta Worley and Meermeier, {Erin W.} and Gwendolyn Swarbrick and Aaron Nilsen and Lewinsohn, {Deborah A.} and William Hildebrand and Adams, {Erin J.} and Lewinsohn, {David M.}",
note = "Funding Information: The following reagents were obtained through the NIH Tetramer Core Facility: MR1/5-OP-RU and MR1/6FP tetramers. The MR1/5-OP-RU tetramer technology was developed jointly by J. McCluskey, J. Rossjohn, and D. Fairlie, and the material was produced by the NIH Tetramer Core Facility as permitted to be distributed by the University of Melbourne (10). This work was funded by the Bill and Melinda Gates Foundation (OPP1131709). This work was also supported in part by Career Development Award #IK2 CX000538 from the U.S. Department of Veterans Affairs Clinical Sciences Research and Development Program (M.J.H.), Merit Award #I01 BX000533 from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Program (D.M.L.), and NIH R01 AI129976 (M.J.H.). The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government. Publisher Copyright: Copyright {\textcopyright} 2018 The Authors, some rights reserved.",
year = "2018",
doi = "10.1126/sciimmunol.aao2556",
language = "English (US)",
volume = "3",
journal = "Science Immunology",
issn = "2470-9468",
publisher = "American Association for the Advancement of Science",
number = "25",
}